<DOC>
	<DOCNO>NCT00114816</DOCNO>
	<brief_summary>This study compare two chemotherapy regimen adjuvant treatment breast cancer . The study participant randomly allocate receive either 3 cycle docetaxel follow 3 cycle CEF ( cyclophosphamide , epirubicin 5-fluorouracil ) receive 3 cycle docetaxel plus capecitabine follow 3 cycle CEX ( cyclophosphamide , epirubicin capecitabine ) . The study participant require medium high risk breast cancer recurrence . The primary aim study investigate whether addition capecitabine standard taxane/anthracycline regimen influence recurrence-free survival .</brief_summary>
	<brief_title>Docetaxel Followed CEF ( Cyclophosphamide , Epirubicin 5-Fluorouracil ) Compared Docetaxel Capecitabine Followed CEX ( Cyclophosphamide , Epirubicin Capecitabine ) Adjuvant Treatment Breast Cancer</brief_title>
	<detailed_description>This open-label , two-arm , randomized multi-center phase III trial compare efficacy safety taxane-anthracycline regimen taxane-anthracycline-capecitabine regimen adjuvant treatment early breast cancer intermediate-to-high risk cancer recurrence . Patients diagnose early breast cancer estimate risk 25 % great distant recurrence within 5 year diagnosis randomly allocate one follow 2 arm ( 1:1 ) : - Arm A -- 3 cycle docetaxel 80 mg/m² intravenous ( i.v . ) ( repeat day [ d. ] 22 ) ; follow 3 cycle CEF ( cyclophosphamide 600 mg/m2 i.v. , epirubicin 75mg/m² i.v. , 5-fluorouracil 600 mg/m2 i.v. , repeat d. 22 ) - Arm B -- 3 cycle TX ( docetaxel 60 mg/m² i.v. , capecitabine twice daily 900 mg/m² give orally day 1-15 cycle ; cycle repeat d. 22 ) ; follow 3 cycle CEX ( cyclophosphamide 600 mg/m2 i.v. , epirubicin 75mg/m² i.v , capecitabine twice daily 900 mg/m² day 1-15 cycle ; cycle repeat d. 22 ) Locoregional radiotherapy give accord institutional practice complete adjuvant chemotherapy ( Tx3/CEFx3 TXx3/CEXx3 ) . All patient ER and/or PgR positive disease receive adjuvant endocrine therapy . This consist 1 mg p.o . anastrozole ( ArimidexR ) give 60 month woman post-menopausal prior chemotherapy ( menstrual period &gt; 6 month ) tamoxifen 20 mg p.o . 60 month woman pre-menopausal prior chemotherapy . Use trastuzumab allow HER-2 positive disease . Patients follow 5 year post-randomization .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Epirubicin</mesh_term>
	<criteria>To eligible inclusion study , patient must fulfill criterion . Have provide write informed consent prior studyspecific screening procedure , understand patient right withdraw study time , without prejudice . Be female 18 year age old . Have histologically confirm invasive breast cancer . High risk breast cancer recurrence ( &gt; 25 % within first 5 year without adjuvant therapy , &gt; 35 % within first 10 year ) one following : Regional node positive disease ( pN+ ; tumor cell tumor cell cluster &lt; 0.2 mm diameter count metastasis ) ; Pathological N0 PgR tumor size &gt; 20 mm . Patients fulfill follow criterion exclude : &gt; 65 year age . ” Special type ” histology ( mucinous , papillary , medullary , tubular breast cancer ) , pN0 . ER , PgR HER2 status ( via situ hybridization immunohistochemistry ) determine . Presence distant metastasis . Previous chemotherapy neoadjuvant setting . Nonambulatory WHO performance status &gt; 1 . Pregnant lactating woman . Women childbearing potential ( menstruate within 6 month study entry hysterectomy age &lt; 55 ) either positive pregnancy test baseline . Women childbearing potential unless use reliable appropriate contraceptive method . ( Postmenopausal woman must amenorrheic least 6 month consider nonchildbearing potential ) . More 12 week breast surgery date randomization . Organ allografts immunosuppressive therapy require . Major surgery ( except breast surgery ) within 4 week prior study treatment start , lack complete recovery effect major surgery . Participation investigational drug study within 4 week precede treatment start . Patients history uncontrolled seizure , central nervous system disorder psychiatric disability judge investigator clinically significant precluding inform consent interfere compliance oral drug intake . History another malignancy within last five year except cure basal cell carcinoma skin carcinoma situ uterine cervix . Clinically significant ( i.e . active ) cardiac disease ( e.g . congestive heart failure , symptomatic coronary artery disease cardiac arrhythmia well controlled medication ) myocardial infarction within last 12 month . Abnormal laboratory value : Hemoglobin &lt; 10.0 g/dL , neutrophils &lt; 1.5 x 10^9/L , platelet count &lt; 120 x 10^9/L ; Serum creatinine &gt; 1.5 x Upper Limit Normal ( ULN ) ; Creatinine clearance ( calculate per Cockroft Gault ) &lt; 50 mL/min ; Serum bilirubin &gt; ULN ; ALAT &gt; 1.5 x ULN ; Alkaline phosphatase &gt; 2.5 x ULN . Serious uncontrolled intercurrent infection serious uncontrolled concomitant disease . Lack physical integrity upper gastrointestinal tract clinically significant malabsorption syndrome . Inability swallow tablet . Life expectancy le 3 month . Unwilling unable comply protocol duration study . Requirement concurrent use antiviral agent sorivudine chemically related analogue , brivudine .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>May 2007</verification_date>
	<keyword>breast cancer</keyword>
	<keyword>chemotherapy</keyword>
	<keyword>adjuvant</keyword>
	<keyword>capecitabine</keyword>
	<keyword>docetaxel</keyword>
</DOC>